Thomas H. Brannagan

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

David Adams, Alejandra González‐Duarte, William O’Riordan et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

Merrill D. Benson, Márcia Waddington‐Cruz, John L. Berk et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis

M. Kittleson, Frederick L. Ruberg, Amrut V. Ambardekar et al. · Journal of the American College of Cardiology · 2023 · 474 citations

Medical Decision Making, Heart Failure, Cardiac Amyloidosis +10

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis

Scott D. Solomon, David Adams, Arnt V. Kristen et al. · Circulation · 2019 · 450 citations

Myasthenic crisis

Charlene Thomas, S. A. Mayer, Yiğit Güngör et al. · Neurology · 1997 · 383 citations